Ser132

Site Information
ssLRRHGsMVsLVsG SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 483985
Associated spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	immunoprecipitation ( 2 , 27 ) , mass spectrometry ( 4 , 5 , 6 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 26 , 29 ) , mass spectrometry (in vitro) ( 3 ) , mutation of modification site ( 1 , 2 , 7 , 16 , 25 , 27 , 28 ) , phospho-antibody ( 2 , 27 ) , western blotting ( 25 )
Disease tissue studied:	breast cancer ( 6 , 9 ) , breast ductal carcinoma ( 6 ) , HER2 positive breast cancer ( 4 ) , luminal A breast cancer ( 4 ) , luminal B breast cancer ( 4 ) , breast cancer, surrounding tissue ( 4 ) , breast cancer, triple negative ( 4 , 6 ) , cervical cancer ( 25 ) , cervical adenocarcinoma ( 25 ) , leukemia ( 14 ) , acute myelogenous leukemia ( 14 ) , liver cancer ( 16 ) , lung cancer ( 2 , 9 ) , non-small cell lung cancer ( 2 , 9 ) , non-small cell lung adenocarcinoma ( 2 ) , prostate cancer ( 19 , 20 ) , teratoma ( 18 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) ( 2 ) , breast ( 4 , 6 ) , BT-20 (breast cell) ( 9 ) , Calu 6 (pulmonary) ( 9 ) , CHO (fibroblast) ( 7 , 25 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 10 ) , Flp-In T-Rex-293 (epithelial) ( 10 ) , H2009 (pulmonary) ( 9 ) , H2077 (pulmonary) ( 9 ) , H2887 (pulmonary) ( 9 ) , H322M (pulmonary) ( 9 ) , HCC2279 (pulmonary) ( 9 ) , HCC827 (pulmonary) ( 9 ) , HEK293T (epithelial) ( 27 ) , HeLa (cervical) ( 1 , 17 , 28 ) , HeLa S3 (cervical) ( 25 ) , HOP62 (pulmonary) ( 9 ) , Huh7 (hepatic) ( 16 ) , Jurkat (T lymphocyte) ( 8 , 11 , 12 , 13 , 15 , 21 , 22 , 23 , 24 , 26 ) , K562 (erythroid) ( 29 ) , KG-1 (myeloid) ( 14 ) , LCLC-103H (pulmonary) ( 9 ) , LNCaP (prostate cell) ( 19 , 20 ) , LOU-NH91 (squamous) ( 9 ) , MCF-7 (breast cell) ( 5 ) , MDA-MB-468 (breast cell) ( 9 ) , NCCIT (epithelial) ( 18 ) , NCI-H1395 (pulmonary) ( 9 ) , NCI-H157 (pulmonary) ( 9 ) , NCI-H1648 (pulmonary) ( 9 ) , NCI-H1666 (pulmonary) ( 9 ) , NCI-H2030 (pulmonary) ( 9 ) , NCI-H2172 (pulmonary) ( 9 ) , NCI-H322 (pulmonary) ( 9 ) , NCI-H460 (pulmonary) ( 9 ) , NCI-H520 (squamous) ( 9 ) , PC9 (pulmonary) ( 9 )

Upstream Regulation
Putative in vivo kinases:	CK1G2 (human) ( 25 ) , PRKD1 (human) ( 16 , 27 )
Kinases, in vitro:	CK1G2 (human) ( 25 ) , PRKD1 (human) ( 27 )

Downstream Regulation
Effects of modification on COL4A3BP:	activity, inhibited ( 1 , 3 , 16 ) , enzymatic activity, inhibited ( 25 , 27 , 28 ) , intracellular localization ( 1 , 25 ) , molecular association, regulation ( 1 , 3 , 28 ) , protein conformation ( 1 , 2 )
Effects of modification on biological processes:	exocytosis, altered ( 27 )
Induce interaction with:	COL4A3BP (human) ( 1 , 28 )

References
1	Sugiki T, et al. (2018) Phosphoinositide binding by the PH domain in ceramide transfer protein (CERT) is inhibited by hyperphosphorylation of an adjacent serine-repeat motif. J Biol Chem 29848549 Curated Info
2	Revert F, et al. (2018) Selective targeting of collagen IV in the cancer cell microenvironment reduces tumor burden. Oncotarget 9, 11020-11045 29541394 Curated Info
3	Prashek J, et al. (2017) Interaction between the PH and START domains of ceramide transfer protein competes with phosphatidylinositol 4-phosphate binding by the PH domain. J Biol Chem 292, 14217-14228 28652409 Curated Info
4	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
5	Sacco F, et al. (2016) Deep Proteomics of Breast Cancer Cells Reveals that Metformin Rewires Signaling Networks Away from a Pro-growth State. Cell Syst 2, 159-71 27135362 Curated Info
6	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
7	Rahimpour A, et al. (2013) Engineering the cellular protein secretory pathway for enhancement of recombinant tissue plasminogen activator expression in Chinese hamster ovary cells: effects of CERT and XBP1s genes. J Microbiol Biotechnol 23, 1116-22 23676904 Curated Info
8	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
9	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
10	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
11	Mulhern D (2012) CST Curation Set: 13827; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R) Curated Info
12	Mulhern D (2012) CST Curation Set: 13828; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R) Curated Info
13	Mulhern D (2012) CST Curation Set: 13830; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R) Curated Info
14	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
15	Mulhern D (2011) CST Curation Set: 13106; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
16	Amako Y, Syed GH, Siddiqui A (2011) Protein Kinase D Negatively Regulates Hepatitis C Virus Secretion through Phosphorylation of Oxysterol-binding Protein and Ceramide Transfer Protein. J Biol Chem 286, 11265-74 21285358 Curated Info
17	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
18	Zhou J (2010) CST Curation Set: 9672; Year: 2010; Biosample/Treatment: cell line, NCCIT/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
19	Zhou J (2009) CST Curation Set: 7214; Year: 2009; Biosample/Treatment: cell line, LNCaP/untreated; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
20	Zhou J (2009) CST Curation Set: 7215; Year: 2009; Biosample/Treatment: cell line, LNCaP/untreated; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
21	Zhou J (2009) CST Curation Set: 6541; Year: 2009; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
22	Zhou J (2009) CST Curation Set: 6542; Year: 2009; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
23	Zhou J (2009) CST Curation Set: 6050; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
24	Zhou J (2009) CST Curation Set: 5901; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
25	Tomishige N, et al. (2009) Casein kinase I{gamma}2 down-regulates trafficking of ceramide in the synthesis of sphingomyelin. Mol Biol Cell 20, 348-57 19005213 Curated Info
26	Zhou J (2008) CST Curation Set: 5470; Year: 2008; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
27	Fugmann T, et al. (2007) Regulation of secretory transport by protein kinase D-mediated phosphorylation of the ceramide transfer protein. J Cell Biol 178, 15-22 17591919 Curated Info
28	Kumagai K, et al. (2007) Interorganelle trafficking of ceramide is regulated by phosphorylation-dependent cooperativity between the PH and START domains of CERT. J Biol Chem 282, 17758-66 17442665 Curated Info
29	Possemato A (2007) CST Curation Set: 2629; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info